Fernando Carreño is a University of North Carolina/GlaxoSmithKline Pharmacokinetics/Pharmacodynamics post-doctoral fellow. He graduated as a Pharmacist from the State University of Maringá in Brazil and obtained his Master’s and PhD degrees in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul in Brazil. Fernando has experience in the application of pharmacometrics tools to evaluate how nanocarriers modulate drug delivery to the brain. His current research interests include population pharmacokinetic/pharmacodynamics and physiologically-based pharmacokinetic (PBPK) modeling of clinical data to characterize drug disposition and individualize dosing in different patient population.
Gustavo Mendes Lima Santos
Gustavo Mendes Lima Santos is general manager of Medicines and Biological Products (GGMED/ANVISA). He got a Degree in Pharmacy in São Paulo University, specialist in Public Health in FIOCRUZ and master’s degree in Toxicology in State University of Londrina. Gustavo has been working over 16 years in National Health Surveillance Agency (ANVISA) in the evaluation of clinical trials of medicines and inspection in research centers.
He is a Senior Lecturer in Pharmaceutics at the University of Hertfordshire. Was awarded a PhD in 2013 from the University of Reading (U.K.) under the supervision of Professor Vitaliy Khutoryanskiy and Professor Dimitris Charalampopoulos on the subject of bacterial microencapsulation. Following this appointment held a position as a Postdoctoral Research Assistant in Professor Khutoranskiy’s group, synthesizing glycopolymer hydrogels as mimics of mucosal tissue. In 2015 he moved to the University of Hertfordshire, where his research has focussed on the generation of thermoresponsive polymer systems with application to healthcare, supported by funding bodies including the EPSRC, the Royal Society, and Animal Free Research UK.
Prof Vitaliy Khutoryanskiy has been Professor of Formulation Science since 2014, having previously been Associate Professor in Pharmaceutical Materials (2010-2014) and Lecturer in Pharmaceutics (2005-2010) at Reading School of Pharmacy, University of Reading (UK). He has researched broadly in the area of new biomaterials for pharmaceutical and biomedical applications, with a particular emphasis on drug delivery, mucoadhesive materials, hydrogels, nanomaterials and stimuli-responsive polymers. He was the recipient of the 2012 McBain Medal from the Society of Chemical Industry (SCI) and Royal Society of Chemistry (RSC) for his imaginative use of colloid, polymer and interface science in the development of novel biomedical materials; he also received PhD Supervisor of the Year Postgrad Award (2020) from FindAPhD. Prof Khutoryanskiy has published 165 original research articles and 24 reviews, accruing over 9300 citations with an h-index of 46 (Google Scholar). He also edited 4 books and filed 3 patent applications. He sits on editorial boards for several journals (European Polymer Journal, Journal of Pharmaceutical Sciences, Pharmaceutics, Polymers, Drug Delivery Letters, and Gels).
Degree in Chemical Engineering from the State University of Maringá (UEM) (2012), Master (2014) and Ph.D (2018) in Chemical Engineering from the State University of Campinas (UNICAMP), with an extension training period at Université Laval (Quebec, Canada) and Colorado State University (Fort Collins, USA). She completed a post-doctorate in Chemical Engineering at UNICAMP (2019) and was a lecturer in the Department of Bioprocesses and Biotechnology at the São Paulo State University (UNESP) (2019). She has experience in the development of polymeric biomaterials with applications as bioactive dressings and as scaffolds for tissue engineering and regenerative medicine. She is currently a Research & Development Engineer at TissueLabs, focused on improving the properties of bioink formulations for the 3D bioprinting of tissues and organs.
Raquel Isolani, graduated in pharmacy from the State University of Maringá, master and PhD student in Pharmaceutical Sciences at the same university, working with natural products and their biological applications. In PhD, she did an exchange for the University of Münster-Germany, at the Institute of Pharmaceutical Biology and Phytochemistry. She is a professor at the Metropolitan University Center of Maringá (Unifamma) in the Pharmacy, Biomedicine and Odontology courses and is a partner-administrator at Startup Salutem Farmacêutica.
John DiBella is President of the Lancaster Division at Simulations Plus. After finishing his graduate studies in Biomedical Engineering from Case Western Reserve University, he joined the company in 2003, initially spending time working on the development of the GastroPlusTM and DDDPlusTM software platforms and serving as technical lead on modeling & simulation consulting projects for sponsor companies. He eventually transitioned to business development before being promoted to his current role in September 2017, where he now leads strategic efforts and continues to travel globally hosting workshops and presenting at conferences.
Helen Colley is a Senior Lecturer in Oral Bioscience within the Faculty of Medicine, Dentistry and Health at the University of Sheffield, UK.
After completing a BSc in Anatomy and Cell Biology she went on to complete a PhD in Tissue-Engineering. She now has over 15 years experience in cell biology with specific interests in epithelium and tissue engineering, in particular the construction and use of 3D multi-cellular in vitro models.
In recent years her laboratory have successfully developed and characterised advanced full thickness constructs to model human skin and oral mucosa to assist in understanding the biology in health and disease. Using these systems, her current research focuses on the development of novel therapeutics and drug delivery mechanisms.
Craig Murdoch is Professor of Oral Bioscience and leads the Integrated Biosciences Group within the School of Clinical Dentistry at the University of Sheffield, UK. He has 15 years’ experience in the field of oral medicine research, working on oral epithelial biology and the molecular mechanisms of oral diseases and their systemic sequalae. Part of his current research encompasses new forms of polymer-based oral drug delivery systems for treatment of oral diseases and systemic applications. He a key member of the University of Sheffield team who have collaborated closely with AFYX Therapeutics to develop the Rivelin oral mucosal patch technology. He has an extensive track record of working on multi-disciplinary research projects and has worked alongside biomaterial scientists, chemists and mathematical modellers on a number of related projects.
Cesar Augusto Tischer
Professor and researcher in the biomaterials field have been publishing in the modification and characterization of biopolymers for medical application. He has PhD in Biochemistry and did his Post-doctorate at CERMAV (France), was an Invited Researcher and Associated Researcher at the University of Ottawa, Canada.
Dr. Martins is Director of PBPK at esqLABS GmbH, Germany. He is Pharmacist with Ph.D. in Science. With over seven years of experience in pharmaceutical Industries and CROs, he developed extensive experience in IVIVE, IVIVC, first-in-human dose selection, and application of PBPK to formulation development. Dr. Martins has several peer-reviewed publications and granted with international funds from FDA and EMA. Dr. Martins also worked as Pharmacometrics Leader at Galapagos in Paris and Research Scientist at Certara, England. His primary focus area at the moment is anti-inflammatory, pulmonary fibrosis, immunology, and skin diseases. Since 2019, Dr. Martins is a visiting professor at the State University of Maringá, Brazil, collaborating with the post-graduate program in pharmaceutical science as graduate students’ co-supervisor.
Paulo Paixão is Assistant Professor of Pharmacokinetics and Biopharmacy at the Faculty of Pharmacy, University of Lisbon. Member of EMA’s PKWP and of the Medicines Evaluation Committee at INFARMED. He participates in evaluating Bioequivalence and Clinical Pharmacokinetics at European and National level. His main research interests are related to pharmacokinetics and therapeutic drug monitoring. In particular, QSAR, in vitro assays and data integration in PBPK models and other modeling and simulation approaches. His work has mainly focused on oral absorption with several papers on bioavailability/bioequivalence at the regulatory level, particularly on establishing pharmacokinetic metrics for bioequivalence of modified release formulations and evaluating similarity metrics for dissolution profiles. Currently, his research interests are also related to better understanding the physiology of the gastrointestinal tract and its consequences on the clinical variability of oral medicines.
Member of the Equivalence and Bioequivalence Thematic Technical Committee of the Brazilian Pharmacopoeia for ten years. Pharmacist by the Federal University of Ouro Preto (UFOP-MG). Master in Chemistry and Doctorate in Health Sciences by the Federal University of Goias (UFG-GO). He has extensive experience in the industry, especially in drug control analysis, focusing in dissolution, cell permeability, bioequivalence/bioavailability, and clinical research. He has published several scientific articles and actively participated in the implementation of generic drugs in Brazil, conducting in vitro and in vivo studies in the country’s largest clinical research center for drug development, the ICF (Institute of Pharmaceutical Sciences), where he has been CEO for over 19 years.
Alexandre José Macedo
Professor at Federal University of Rio Grande do Sul, Brazil, since 2007. Has experience in microbiology focusing on bioactive metabolites production and bacterial adhesion inhibition. Published more than 110 international scientific articles, four patents and advisor of more than 60 students in all levels. Head of Group Biofilms & Microbial diversity. Practice in chemical, analytical and microbiological laboratories since 1989. Co-founder of startup company REGENERA Biotechnology.
Dr. Ramendra Pati Pandey
Dr. Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow (from September 2015- January 2019), at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, School of Medicine, Brazil. He was working on New therapies for Chagas disease: Using repurposing of drugs acting on the Cell invasion and Autophagy progression of host cells and Potentiation of drug effect using Biopolymeric nanoparticulate Drug Delivery Systems against Trypanosoma cruzi. He was a Research Associate (from September 2013-August 2015) at the Translational Health Science and Technology Institute, Faridabad-Gurgaon Expressway, Faridabad Gurgaon, India. Where he and his group has identified Transcription factor Foxo1 is essential for IL-9 induction in T helper cells, and this work has been published in Nature Communications Journal. And, there was one patent (Application Number-(E-5/1022/2016) on Therapeutic evaluation of Compound 1. He has been selected and received the Early Career Scientist Award from the British council and the Newton Fund (2019), Member of the Royal Society of Tropical Medicine and Hygiene, Admitted to membership of the Royal Society of Chemistry, and International Scientist Award (2020). Recently he has been elected as a member of the National Academy of Sciences, India (2021).